This document includes updated breakpoint and quality control tables for the Clinical and Laboratory Standards Institute susceptibility testing standard M24.

A CLSI supplement for global application.
Performance Standards for Susceptibility Testing of Mycobacteria, *Nocardia* spp., and Other Aerobic Actinomycetes

Nicole M. Parrish, PhD, MHS, D(ABMM)
Nancy L. Wengenack, PhD, D(ABMM)
Adam Barker, PhD
Barbara A. Brown-Elliott, MS, MT(ASCP)SM
Daniela Maria Cirillo, MD, PhD
Susan Harrington, PhD, D(ABMM), MLS(ASCP)CM
Reeti Khare, PhD, D(ABMM)
Scott B. Killian, BS
Richard Pfeltz, PhD
Elvira Richter, PhD
Marie-Claire Rowlinson, PhD, D(ABMM)
Adrian M. Zelazny, PhD, D(ABMM)

Abstract

Clinical and Laboratory Standards Institute document M24S—*Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes* includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24.1 The data in the tables are valid only when the methodology in CLSI document M241 is followed.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100   F: +1.610.688.0700   E: customerservice@clsi.org   W: www.clsi.org
Contents

Abstract .............................................................................................................. i

Committee Membership .................................................................................. iii

Overview of Changes ...................................................................................... vii

Abbreviations and Acronyms ........................................................................... xi

Reference .......................................................................................................... xii

Table 1. Broth Microdilution Breakpoints and Interpretive Categories for MTBC Tested in Middlebrook 7H9 Broth Supplemented With OADC Using MIC Panels........................................ 1

Table 2. Susceptibility Testing of MTBC to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System .............................................. 3

Table 3. Antimicrobial Agents and Breakpoints for Testing MAC ....................... 6

Table 4. Antimicrobial Agents and Breakpoints for Testing Mycobacterium kansasii .. 8

Table 5. Antimicrobial Agents and Breakpoints for Testing Slowly Growing Nontuberculous Mycobacteria Other Than MAC and Mycobacterium kansasii ............. 9

Table 6. Antimicrobial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria ................................................................................................................... 10

Table 7. Antimicrobial Agents and Breakpoints for Testing Nocardia spp. and Other Aerobic Actinomycetes ................................................................. 13

Table 8. Expected Antimicrobial Susceptibility Patterns of the Most Commonly Isolated Nocardia spp. .................................................................................................. 15

Table 9. Expected Results for Routine and Supplemental QC Strains When Testing MTBC by a Culture-based Method ................................................................. 17

Table 10. MIC QC Ranges When Testing MTBC Using Mycobacterium tuberculosis ATCC® 27294 (H37Rv) Tested in Middlebrook 7H9 Medium Supplemented With OADC .......... 18

Table 11. QC Ranges for Susceptibility Testing of Mycobacterium tuberculosis ATCC® 27294 (H37Rv) to Second-Line Drugs Using the Fluorescence-based Commercial Shorter-Incubation Liquid Media System ......................................... 20


Contents (Continued)


The Quality Management System Approach .......................................................... 27
Table 1. Broth Microdilution Breakpoints and Interpretive Categories for MTBC Tested in Middlebrook 7H9 Broth Supplemented With OADC Using MIC Panels¹⁻³

<table>
<thead>
<tr>
<th>QC Recommendation (see Table 10 for acceptable QC ranges)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine QC strain:</td>
</tr>
<tr>
<td>- Mycobacterium tuberculosis ATCC® 27294 (H37Rv)</td>
</tr>
</tbody>
</table>

General Comments

(1) ATCC® is a registered trademark of the American Type Culture Collection.

(2) This table contains updated information and notifies laboratories of important changes among published versions of CLSI document M24.⁴

(3) The breakpoints in Table 1 were established using lyophilized MIC panels incubated in 5% to 10% CO₂. Incubating tests in ambient air may result in erroneous MICs because MTBC grow more slowly in ambient air. If preparing in-house MIC panels, care should be taken to match the manufacturer’s formulation because the use of polysorbate or glycerol in the broth may affect the MIC values obtained.

(4) This antimicrobial susceptibility testing system is not regulatory organization cleared.

NOTE: Information in black boldface type is new or modified since the previous edition.

<table>
<thead>
<tr>
<th>Antimicrobial Agent</th>
<th>MIC Breakpoints, µg/mL</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethambutol</td>
<td>≤ 2</td>
<td>S</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Inconclusive</td>
</tr>
<tr>
<td></td>
<td>≥ 8</td>
<td>R</td>
</tr>
</tbody>
</table>

(5) Inconclusive MIC for ethambutol. An MIC of 4 µg/mL obtained by broth microdilution using lyophilized panels does not correlate with either a susceptible or resistant result in commercial automated, short-incubation broth systems, and there are no clinical data correlating such a result with ethambutol treatment response. NOTE: Repeat testing using an alternative broth method (e.g., critical concentration) or genotypic method may determine whether the isolate in question is susceptible or resistant.
Table 6. Antimicrobial Agents and Breakpoints for Testing Rapidly Growing Mycobacteria

QC Recommendations (see Table 13 for acceptable QC ranges)

Routine QC strain:
- Mycobacterium peregrinum ATCC® 700686

Supplemental QC strains:
- Staphylococcus aureus ATCC® 29213
- Enterococcus faecalis ATCC® 29212 and/or Pseudomonas aeruginosa ATCC® 27853 may also be used, if desired.

General Comment

(1) ATCC® is a registered trademark of the American Type Culture Collection.

NOTE: Information in black boldface type is new or modified since the previous edition.

<table>
<thead>
<tr>
<th>Antimicrobial Agent</th>
<th>MIC, µg/mL</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S</td>
<td>I</td>
</tr>
<tr>
<td>Amikacin (IV)</td>
<td>≤ 16</td>
<td>32</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>≤ 16</td>
<td>32–64</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>≤ 1</td>
<td>2</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>≤ 2</td>
<td>4</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>≤ 1</td>
<td>2-4</td>
</tr>
</tbody>
</table>